Literature DB >> 19224787

Relative analgesic potencies of levobupivacaine and ropivacaine for caudal anesthesia in children.

Pablo Ingelmo1, Geoff Frawley, Marinella Astuto, Chris Duffy, Susan Donath, Nicola Disma, Giuseppe Rosano, Roberto Fumagalli, Antonio Gullo.   

Abstract

BACKGROUND: Comparing relative potency of new local anesthetics, such as levobupivacaine and ropivacaine, by the minimum local analgesic concentration model has not been described for caudal anesthesia. Therefore, we performed a prospective, randomized, double-blind study to determine the minimum local analgesic concentrations of a caudal single shot of ropivacaine and levobupivacaine in children and to describe the upper dose-response curve.
METHODS: We performed a two-stage prospective, randomized, double-blind study comparing the dose-response curves of caudal ropivacaine and levobupivacaine in children. In phase 1, 80 boys were randomized to receive either ropivacaine or levobupivacaine. In the second phase a further 32 patients were randomly allocated to receive caudal anesthesia with doses designed to delineate the upper dose-response range (the 50% effective dose [ED(50)]-ED(95) range).
RESULTS: There were no significant differences in ED(50) values for caudal ropivacaine and levobupivacaine. The ED(50) for levobupivacaine estimated from the Dixon Massey method was 0.069% (95% CI 0.056%-0.082%) and for ropivacaine was 0.075% (95% CI 0.058%-0.092%). Estimated by isotonic regression the ED(50) and ED(95) respectively of levobupivacaine were 0.068 (0.04-0.09) and 0.20% (95% CI 0.16%-0.24%). For ropivacaine ED 50 and ED95 were 0.066 (0.033-0.098) and 0.225% (95% CI 0.21%-0.24%).
CONCLUSIONS: In children receiving one minimum alveolar anesthetic concentration of sevoflurane, there were no significant differences in the ED(50) for caudal levobupivacaine and ropivacaine. The potency ratio at ED(50) was 0.92 and 0.89 at ED(95), indicating that caudal levobupivacaine and ropivacaine have a similar potency.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19224787     DOI: 10.1213/ane.0b013e3181935aa5

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  4 in total

Review 1.  Clinical Pharmacokinetics and Pharmacodynamics of Levobupivacaine.

Authors:  Chantal A A Heppolette; Derek Brunnen; Sohail Bampoe; Peter M Odor
Journal:  Clin Pharmacokinet       Date:  2020-06       Impact factor: 6.447

2.  The minimum effective concentration (MEC90) of ropivacaine for ultrasound-guided caudal block in anorectal surgery. A dose finding study.

Authors:  Xuehan Li; Jun Li; Pei Zhang; Huifei Deng; Mingan Yang; Hongbo He; Rurong Wang
Journal:  PLoS One       Date:  2021-09-17       Impact factor: 3.240

3.  Comparison of 0.5% Ropivacaine and 0.5% Levobupivacaine for Sciatic Nerve Block Using Labat Approach in Foot and Ankle Surgery.

Authors:  Khushboo Malav; Geeta Singariya; Sadik Mohammed; Manoj Kamal; Pushpender Sangwan; Bharat Paliwal
Journal:  Turk J Anaesthesiol Reanim       Date:  2017-11-27

4.  Effect of caudal ketamine on minimum local anesthetic concentration of ropivacaine in children: a prospective randomized trial.

Authors:  Huai-Zhen Wang; Ling-Yu Wang; Hui-Hong Liang; Yan-Ting Fan; Xing-Rong Song; Ying-Jun She
Journal:  BMC Anesthesiol       Date:  2020-06-08       Impact factor: 2.217

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.